Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Always match the form to your primary goal
In the LEADER trial (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results), researchers found that liraglutide reduced the risk of cardiovascular events in diabetic patients, including heart attack, stroke, and cardiovascular death, by 13% compared to placebo
Not all are informed
There is also a serotonergic component
No insurance is required, and the medication is HSA/FSA eligible, making the transition financially accessible for most patients
US$ 27.14
US$ 21.33
US$ 26.37
